文献速递胸部肿瘤放疗

PD-L1抑制剂联合胸部放疗一线治疗广泛期小细胞肺癌的真实世界结局

Real-world outcomes of PD-L1 inhibitors combined with thoracic radiotherapy in the first-line treatment of extensive stage small cell lung cancer.
PubMed 文献 · Radiat Oncol · 2023-07-04

本研究纳入2019年1月至2021年12月接受度伐利尤单抗或阿替利珠单抗联合化疗一线治疗的广泛期小细胞肺癌患者211例,按是否接受胸部放疗分为两组并行1:1倾向性评分匹配。结果显示加用胸部放疗可显著改善无进展生存和总生存,但治疗相关性肺炎发生率增加,多为1-2级。

要点

  • 在全部患者中,胸部放疗组中位无进展生存9.5个月 vs 非胸部放疗组7.2个月(HR=0.59,95%CI 0.39-0.88,p=0.009)。
  • 胸部放疗组中位总生存24.1个月 vs 非胸部放疗组18.5个月(HR=0.53,95%CI 0.31-0.89,p=0.016)。
  • 加用胸部放疗增加治疗相关性肺炎发生率(p=0.018),大多数为1-2级,对症治疗后可缓解。

核心结论

  • 在度伐利尤单抗或阿替利珠单抗联合化疗基础上加用胸部放疗可显著改善广泛期小细胞肺癌患者的生存。
  • 加用胸部放疗可能增加治疗相关性肺炎发生率,但大多数病例经对症治疗后可缓解。

研究设计与样本

  • 本研究为真实世界研究,纳入2019年1月至2021年12月接受度伐利尤单抗或阿替利珠单抗联合化疗作为广泛期小细胞肺癌一线治疗的患者。
  • 共纳入211例患者,其中70例(33.2%)接受标准治疗加胸部放疗,141例(66.8%)对照组接受PD-L1抑制剂联合化疗。
  • 采用1:1倾向性评分匹配(PSM),匹配后共57对患者纳入分析。
  • 主要终点为无进展生存(PFS)、总生存(OS)和安全性。

主要发现

  • 在全部患者中,胸部放疗组中位无进展生存9.5个月 vs 非胸部放疗组7.2个月(HR=0.59,95%CI 0.39-0.88,p=0.009)。
  • 胸部放疗组中位总生存24.1个月 vs 非胸部放疗组18.5个月(HR=0.53,95%CI 0.31-0.89,p=0.016)。
  • 多因素分析显示,基线肝转移和转移灶数量≥3个是总生存的独立预后因素。
  • 加用胸部放疗增加治疗相关性肺炎发生率(p=0.018),大多数为1-2级。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The CREST study showed that the addition of thoracic radiotherapy (TRT) could improve the survival rate in patients with extensive stage small cell lung cancer (ES-SCLC), but whether TRT can bring survival benefit in the era of immunotherapy remains controversial. This study aimed to explore the efficacy and safety of adding TRT to the combination of PD-L1 inhibitors and chemotherapy. METHODS: The patients who received durvalumab or atezolizumab combined with chemotherapy as the first-line treatment of ES-SCLC from January 2019 to December 2021 were enrolled. They were divided into two groups, based on whether they received TRT or not. Propensity score matching (PSM) with a 1:1 ratio was performed. The primary endpoints were progression-free survival (PFS), overall survival (OS) and safety. RESULTS: A total of 211 patients with ES-SCLC were enrolled, of whom 70 (33.2%) patients received standard therapy plus TRT as first-line treatment, and 141 (66.8%) patients in the control group received PD-L1 inhibitors plus chemotherapy. After PSM, a total of 57 pairs of patients were enrolled in the analysis. In all patients, the median PFS (mPFS) in the TRT and non-TRT group was 9.5 and 7.2 months, respectively, with HR = 0.59 (95%CI 0.39-0.88, p = 0.009). The median OS (mOS) in the TRT group was also significantly longer than that in the non-TRT group (24.1 months vs. 18.5 months, HR = 0.53, 95%CI 0.31-0.89, p = 0.016). Multivariable analysis showed that baseline liver metastasis and the number of metastases ≥ 3 were independent prognostic factors for OS. Addition of TRT increased the incidence of treatment-related pneumonia (p = 0.018), most of which were grade 1-2. CONCLUSIONS: Addition of TRT to durvalumab or atezolizumab plus chemotherapy significantly improves survival in ES-SCLC. Although it may leads to increased incidence of treatment-related pneumonia, a majority of the cases can be relieved after symptomatic treatment.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Peng J, Zhang L, Wang L, et al. Real-world outcomes of PD-L1 inhibitors combined with thoracic radiotherapy in the first-line treatment of extensive stage small cell lung cancer. Radiat Oncol. 2023. PMID: 37403111. doi:10.1186/s13014-023-02308-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。